PD-L1 Expression and Quantitative Assessment of Tumor-Infiltrating T Cell Subsets in Carcinoid Tumors and Large Cell Neuroendocrine Carcinomas of the Lung Abstract #1672

Introduction: Little is known about the expression of PD-L1 an the immune infiltrate in neuroendocrine neoplasms of the lung.
Aim(s): To assess the immune environment in pulmonary carcinoids and large-cell neuroendocrine carcinoma (LCNEC) of the lung.
Materials and methods: Sixty-five resected lung NE tumors (49 typical carcinoids (TC), 5 atypical carcinoids (AC) and 11 LCNEC) were studied. Automated immunohistochemistry for PD-L1 (clone E1L3N), CD8 (clone SP16) and FoxP3 (clone SP97) was performed on whole tissue sections from formalin fixed paraffin-embedded tumor samples. Densities of CD8+ and FoxP3+ cells were assessed at the invasion margin (InvM) and in the tumor center (TumC) by image analysis using Definiens Developer XD software under the supervision of a pathologist.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Dr Julien Hadoux

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2198 PD-L1 Expression and Its Clinical Relevance in Neuroendocrine Tumors of the Lung
Introduction: Immune checkpoint regulation seems to be crucial for nonneuroendocrine lung cancer patients. However, little is known in lung neuroendocrine tumors.
Conference: 15th Annual ENETS conference (2018)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Atsuko Kasajima
Keywords: Lung NEN, PD-L1, Prognosis
#1630 The Positive Expression of PD-L1/PD-1 in Gastroenteropancreatic Neuroendocrine Neoplasias Correlates with Prognosis
Introduction: The incidence of Neuroendocrine Neoplasias (NENs) is increasing and their pathological characteristics, varied between races. However, the epidemiology of GEP-NENs in Chinese patients remains poorly characterized especially for the expression of important immune checkpoint protein PD1 and PD-L1.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Wu Yinying
Authors: Yinying W, Chuying W, ...
#2037 Stromal Immune Contexture Predicts Disease-Free Survival in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs)
Introduction: Stromal Immune Contexture (SIC) helps predict prognosis in solid Tumors (T) but has been poorly investigated in gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs). We tested whether GEP-NENs profiling for adaptive immunity-related SIC markers, as well as inflammatory (COX2),EMT [Beta-catenin (B-cat)] and oncogenic pathway signaling (pS6) markers,could improve Ki67 and/or MO-based prediction of OS and DFS.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD, PhD Massimo Milione
#1780 PD-L1 Is Expressed in a Subset of Pancreatic Neuroendocrine Tumors (pNET)
Introduction: Programmed death 1 (PD-1) is an immune inhibitory receptor expressed on several immune cells, interacting with two ligands, PD-L1 and PD-L2. The former is expressed in many human cancers and is used as a selection criterion for indication of checkpoint inhibitor therapies. PD-L1 is also a potential target for checkpoint inhibitors in pNET therapy, however no data on prevalence of PD-L1 expression and potential associations to clinico-pathologic features is available.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MMed Charalampos Saganas
#1199 Tumor Infiltrating Lymphocytes and PD-L1 Expression Differ in Low and High Grade Neuroendocrine Tumors
Introduction: Although much progress has been made in the past 2-3 years in terms of understanding signaling pathways in gastroenteropancreatic neuroendocrine tumors (GEP-NENs), approved treatment options are still limited. Cancer Immunotherapy has been announced as the breakthrough of the year in 2013 and might become an integral part of the clinical management strategy for solid tumors including GEP-NENs. Therefore, to develop immunotherapeutic strategies against NENs we need to know which immune escape mechanisms are relevant in high and low grade NEC/NENs.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: PD Dr. Patricia Grabowski